Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

In multiple myeloma patients, autologous stem cell transplants abrogate the difference of treating them with two or three drug combinations: Real world data from a single institution in a middle-income country.

View Full Paper
Ask AI
Bookmark
Share

Authors

OLOlivia D. LaraMCMiryea CisnerosMCMiguel Gómez Cabrera

Discussion

Loading...

Member takes

Implication

Retrospective analysis reveals consolidation therapy improves overall survival in multiple myeloma patients, suggesting cost-effective treatment strategies.

Key Points

  • Autologous stem cell transplant significantly improves overall survival in patients with multiple myeloma.
  • Median overall survival is 230.7 months for dual therapy and 58.8 months for triple therapy, p = 0.0061.
  • Retrospective cohort study evaluated patients with multiple myeloma using Kaplan-Meier survival analysis.
  • Findings highlight the role of autologous stem cell transplant in treating advanced multiple myeloma.

Cite This Study

Lara et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d622https://doi.org/10.1182/blood-2025-7604
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Second autologous transplantation remains a valid consolidation option in patients with relapsed multiple myeloma: A report from the Latin American bone marrow transplantation group2025
  2. 2Single versus double autologous stem cell transplantation and lenalidomide maintenance versus no maintenance therapy in newly-diagnosed patients with multiple myeloma: a real-life, vintage snapshot after twenty-three years from the Rete Ematologica Pugliese2025
  3. 3Bortezomib-bendamustine-melphalan or high-dose melphalan in autologous hematopoietic stem cell transplantation for previously transplanted relapsed multiple myeloma – a single center retrospective cohort study2025
  4. 4Clinical outcomes and barriers of autologous hematopoietic stem cell transplantation in newly diagnosed high-risk multiple myeloma in a non-transplant center: Assessing the impact of transplant accessibility on racial minorities2025
  5. 5Treatment Outcomes of Multiple Myeloma in Developing Countries: A Systematic Review and Meta-Analysis2025 · 2 citations